What Happened
- Scientists are testing whether gene-editing techniques — specifically CRISPR-based base editing — can offer a one-time therapeutic fix for dangerously high cholesterol (hypercholesterolemia) by permanently modifying the genetic instructions that regulate cholesterol production in the liver.
- Early Phase 1 clinical trials by Verve Therapeutics using CRISPR base editing to disable the PCSK9 gene in the liver have shown that in three patients receiving the highest doses, blood levels of functional PCSK9 protein dropped 47–84%, and LDL ("bad") cholesterol levels fell 39–55%.
- A separate Phase 1, first-in-human trial of a CRISPR-Cas9 therapy targeting the ANGPTL3 gene (which controls triglyceride metabolism) demonstrated safety and reduced LDL cholesterol by nearly 50% while also lowering triglycerides.
- Scribe Therapeutics' STX-1150, an epigenetic silencing approach targeting the PCSK9 gene, was expected to enter Phase 1 human trials in 2026.
- While results are promising, researchers caution that gene editing for chronic conditions requires rigorous long-term safety monitoring for off-target effects, and existing cholesterol medications (statins, PCSK9 inhibitor injections) remain the standard of care for the foreseeable future.
Static Topic Bridges
CRISPR and Gene Editing: Mechanism and Types
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a naturally occurring bacterial immune system repurposed as a precision gene-editing tool. In the standard CRISPR-Cas9 system, a guide RNA (gRNA) directs the Cas9 enzyme — a molecular "scissors" — to a specific DNA sequence, where it makes a double-strand break. The cell's repair mechanisms then allow gene knockout (disabling a gene) or insertion of new genetic material. Base editing, a second-generation CRISPR variant, uses a modified Cas9 (catalytically impaired, "dead Cas9" fused to a deaminase enzyme) to chemically convert one DNA base to another (e.g., C to T, or A to G) without making a double-strand break — offering greater precision and lower risk of unintended mutations. Prime editing, an even newer variant, acts like a "search and replace" function and can make all 12 types of base-to-base conversions plus small insertions and deletions.
- CRISPR-Cas9: discovered in bacteria; 2020 Nobel Prize in Chemistry awarded to Jennifer Doudna and Emmanuelle Charpentier for its development as a gene-editing tool
- Base editing: developed by David Liu (Broad Institute, MIT/Harvard); avoids double-strand DNA breaks; higher precision
- Prime editing: also developed by David Liu; most versatile, can rewrite ~89% of known disease-causing mutations
- PCSK9 gene: encodes Proprotein Convertase Subtilisin/Kexin Type 9 — a liver protein that degrades LDL receptors; disabling PCSK9 increases LDL receptor recycling, lowering blood LDL
- ANGPTL3 gene: encodes Angiopoietin-Like Protein 3; regulates lipid metabolism; loss-of-function mutations naturally associated with very low cardiovascular risk in humans
- LNP (Lipid Nanoparticle) delivery: the gene-editing components are delivered to liver cells via lipid nanoparticles — the same delivery technology used in mRNA COVID-19 vaccines
Connection to this news: The cholesterol trials use base editing (not standard CRISPR-Cas9) because cholesterol regulation requires a precise single-base change in PCSK9 to mimic the naturally protective loss-of-function mutations seen in people who are genetically immune to high LDL — a task that base editing performs without the risks of double-strand breaks.
Cardiovascular Disease, Cholesterol, and Non-Communicable Disease Burden
Cardiovascular disease (CVD) is the leading cause of death globally, accounting for approximately 17.9 million deaths per year (WHO, 2023). High LDL cholesterol is the primary modifiable risk factor for CVD, driving the formation of atherosclerotic plaques in arterial walls. Familial Hypercholesterolemia (FH) — a genetic disorder causing severely elevated LDL from birth — affects approximately 1 in 250 people globally (31 million people) and dramatically increases heart attack risk. Statins (HMG-CoA reductase inhibitors, e.g., atorvastatin, rosuvastatin) are the current first-line therapy; injectable PCSK9 inhibitor antibodies (evolocumab, alirocumab) are second-line for statin-intolerant or very high-risk patients. India faces a particularly high CVD burden: CVDs account for approximately 27% of all deaths in India, with Indians having a genetic predisposition to early-onset coronary artery disease.
- Global CVD deaths: ~17.9 million/year (WHO 2023); ~31% of all global deaths
- LDL ("bad") cholesterol: primary driver of atherosclerosis; target levels vary by risk — <70 mg/dL for very high-risk patients
- Familial Hypercholesterolemia (FH): affects ~1 in 250 people globally; autosomal dominant; PCSK9, LDLR, ApoB gene mutations
- Statins: first-line therapy; reduce LDL by 30–55%; side effects include myopathy
- PCSK9 inhibitor antibodies (evolocumab/alirocumab): reduce LDL by 50–65%; bi-monthly injections; expensive (~$5,000–$14,000/year)
- India's CVD burden: ~27% of deaths; Indians have smaller coronary arteries and higher visceral fat predisposition
Connection to this news: A one-time gene-editing intervention targeting PCSK9 would eliminate the need for lifelong statin or injection regimens, with profound implications for patient adherence, healthcare costs, and CVD prevention — especially in India where medication adherence for chronic conditions is poor.
Gene Therapy Regulation in India: DBT and ICMR Framework
India's regulatory framework for gene editing and gene therapy is overseen by the Department of Biotechnology (DBT) under the Ministry of Science and Technology. The Review Committee on Genetic Manipulation (RCGM) under DBT monitors research involving genetic modification of organisms and human cell lines. The Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health and Family Welfare regulates clinical trials of gene therapy products as advanced therapy medicinal products (ATMPs) under Schedule Y of the Drugs and Cosmetics Act, 1940 (amended). The Indian Council of Medical Research (ICMR) National Guidelines for Stem Cell Research (2017) and the National Guidelines for Biomedical and Health Research (2017) provide ethical oversight. India has indigenous CRISPR research capability: CSIR-Institute of Genomics and Integrative Biology (IGIB) has developed a modified CRISPR system (enFnCas9) and is pursuing India's first CRISPR therapy for sickle cell disease (in collaboration with AIIMS Delhi).
- RCGM (Review Committee on Genetic Manipulation): DBT-constituted; oversees all genetic manipulation research in India
- CDSCO: regulates clinical trials; gene therapy products classified as ATMPs under Drugs and Cosmetics Act, 1940
- ICMR National Guidelines for Biomedical Research (2017): covers genetic research ethics, consent, and oversight
- CSIR-IGIB + AIIMS Delhi: developing enFnCas9-based CRISPR therapy for sickle cell disease — India's first CRISPR clinical candidate
- India's sickle cell disease burden: ~20 million carriers, ~400,000 patients — the world's second largest burden
- National Sickle Cell Anaemia Elimination Mission (2023): target to eliminate sickle cell disease by 2047; gene therapy is a long-term pillar
Connection to this news: As international CRISPR cholesterol trials advance toward Phase 2 and eventual approval, India's regulatory pathway (CDSCO-RCGM-ICMR) will be critical for determining when such therapies become accessible to Indian patients — particularly given India's high CVD burden and the cost advantage of domestically manufactured gene therapies over imported biologic injections.
Key Facts & Data
- 2020 Nobel Prize in Chemistry: Jennifer Doudna and Emmanuelle Charpentier for CRISPR-Cas9
- PCSK9 base editing trial (Verve Therapeutics): 47–84% PCSK9 protein reduction; 39–55% LDL reduction in Phase 1
- ANGPTL3 CRISPR-Cas9 trial: ~50% LDL reduction + triglyceride reduction; Phase 1 (2025-26)
- Familial Hypercholesterolemia: affects ~1 in 250 people globally (31 million total)
- CVD: 17.9 million deaths/year globally; ~27% of India's annual deaths
- LNP delivery: same technology as mRNA COVID-19 vaccines
- India's CRISPR: CSIR-IGIB enFnCas9 therapy for sickle cell disease (India's first CRISPR candidate)
- National Sickle Cell Anaemia Elimination Mission (2023): target 2047
- CDSCO + RCGM: joint regulators for gene therapy clinical trials in India